This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
Phase 1
Withdrawn
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT03343678
Real World Glycemic Effectiveness of Linagliptin
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11001
- Registration Number
- NCT03338803
- Locations
- 🇺🇸
Optum, Eden Prairie, Minnesota, United States
A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT03332212
- Locations
- 🇬🇧
John Radcliffe Hospital, Oxford, United Kingdom
This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT03325712
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT03315936
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 444
- Registration Number
- NCT03313180
- Locations
- 🇫🇷
HOP Pasteur, Nice, France
🇦🇷Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires, Argentina
🇦🇷CEMER-Centro Medico De Enfermedades Respiratorias, Florida, Argentina
This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT03307252
- Locations
- 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany
Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT03302078
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT03302091
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1008
- Registration Number
- NCT03285373
- Locations
- 🇪🇸
Hospital Dr. José Molina Orosa, Arrecife, Las Palmas, Spain
🇪🇸Hospital Infanta Cristina, Badajoz, Spain
🇪🇸Hospital Universitario de Bellvitge, Hospitalet De Ll (Barcelona), Spain
© Copyright 2025. All Rights Reserved by MedPath